Precision medicine firm Tempus raises $110M in new funding

Tempus, a health IT company advancing precision medicine, received $110 million in as Series E financing round, increasing its total funding to $320 million.

Advertisement

Tempus’ platform builds comprehensive molecular and clinical data sets, leveraging machine learning, sequencing and artificial intelligence-assisted image recognition to offer analysis of and insights into the data.

The company will use the funds to grow operations and expand into new therapeutic areas and geographies.

Additionally, Tempus has collaboration agreements with CancerLinQ, a nonprofit subsidiary of the American Society of Clinical Oncology as well as academic medical centers and National Cancer Institute-designated cancer centers, hospital networks and physicians.

More articles on precision medicine:
Garmin expands work in cardiac health
NIH awards consortium $6.5M to create predictive models for precision medicine
Boston Children’s Hospital to sequence 3K patients’ DNA to study epilepsy, digestive disease

 

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Artificial Intelligence

Advertisement

Comments are closed.